Though Melgain was the only proven remedy available for treating Vitiligo patches, the drug somehow did not become popular on account of limited marketing efforts made by the developer of the product, according to Alok Sonig, head of India sales division of Dr Reddy’s.
The company claims Melgain leads to re-pigmentation in 80 per cent to 90 per cent of the patients as compared with 60 per cent of patients who respond to other treatment such as corticosteroids and photo therapy.
As 3-5 per cent of the population suffers from Vitiligo, Dr Reddy’s would create awareness about the efficacy of the drug among skin specialists and thereby increase its market presence, Sonig said.
Dermatology products contribute less than 10 per cent to its revenues, according to Sonig. He, however, said Dr Reddy’s planned to come out with more products, some in the lifestyle segment , with a target to become one of the top 5 companies in skin care area.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)